Your browser doesn't support javascript.
loading
High Rates of Missed HIV Testing Among Oral PrEP Users in the United States From 2018-2021: A National Assessment on Compliance With HIV Testing Recommendations of the CDC PrEP Guidelines.
Baron, Jason; Tchelidze, Tamar; LaBrot, Benjamin; Yao, Joseph; Mayer, Kenneth H; Kuritzkes, Daniel; Robinson, Nicole; Patel, Rupa R.
Afiliação
  • Baron J; Roche Diagnostics, Indianapolis, Indiana, USA.
  • Tchelidze T; Roche Diagnostics, Indianapolis, Indiana, USA.
  • LaBrot B; Roche Molecular Systems, Pleasanton, California, USA.
  • Yao J; Mayo Clinic, Rochester, Minnesota, USA.
  • Mayer KH; Fenway Health and Harvard Medical School, Boston, Massachusetts.
  • Kuritzkes D; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Robinson N; Roche Diagnostics, Indianapolis, Indiana, USA.
  • Patel RR; Washington University School of Medicine, St Louis, Missouri, USA.
Open Forum Infect Dis ; 11(5): ofae254, 2024 May.
Article em En | MEDLINE | ID: mdl-38798900
ABSTRACT

Background:

The US Centers for Disease Control and Prevention recommends HIV testing every 3 months in oral PrEP users. We performed a national assessment of HIV testing compliance among oral PrEP users.

Methods:

We analyzed 408 910 PrEP prescriptions issued to 39 809 PrEP users using a national insurance claims database that contained commercial and Medicaid claims. We identified PrEP use based on pharmacy claims and outpatient diagnostic coding. We evaluated the percentage of PrEP prescription refills without HIV testing (identified by CPT codes) within the prior 3, 6, and 12 months using time to event methods. We performed subgroup and multivariate analyses by age, gender, race, insurance type, and geography.

Results:

Of 39 809 persons, 36 197 were commercially insured, 3612 were Medicaid-insured, and 96% identified as male; the median age (interquartile range) was 34 (29-44) years, and the Medicaid-insured PrEP users were 24% Black/African American, 44% White, and 9% Hispanic/Latinx. Within the prior 3, 6, and 12 months, respectively, the percentage of PrEP prescription fills in individuals without HIV Ag/Ab testing was 34.3% (95% CI, 34.2%-34.5%), 23.8% (95% CI, 23.7%-23.9%), and 16.6% (95% CI, 16.4%-16.7%), and the percentage without any type of HIV test was 25.8% (95% CI, 25.6%-25.9%), 14.6% (95% CI, 14.5%-14.7%), and 7.8% (95% CI, 7.7%-7.9%).

Conclusions:

Approximately 1 in 3 oral PrEP prescriptions were filled in persons who had not received an HIV Ag/Ab test within the prior 3 months, with evidence of health disparities. These findings inform clinical PrEP monitoring efforts and compliance with national HIV testing guidance to monitor PrEP users.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos